2020
Musculoskeletal Pain Symptoms and Injuries Among Endoscopists Who Perform ERCP
Campbell EV, Muniraj T, Aslanian HR, Laine L, Jamidar P. Musculoskeletal Pain Symptoms and Injuries Among Endoscopists Who Perform ERCP. Digestive Diseases And Sciences 2020, 66: 56-62. PMID: 32144599, DOI: 10.1007/s10620-020-06163-z.Peer-Reviewed Original ResearchConceptsEndoscopic retrograde cholangiopancreatographyMusculoskeletal pain symptomsPain symptomsRisk factorsMusculoskeletal injuriesPrevalent musculoskeletal injuriesDe Quervain's tenosynovitisPotential risk factorsRisk of injuryAnonymous electronic surveyNeck painBack painQuervain's tenosynovitisRetrograde cholangiopancreatographyResultsA totalPreventative strategiesConclusionsThe majorityInjurySymptomsEndoscopistsProtective gearMultiple studiesHalf reportTenosynovitisElectronic survey
2013
Natural history of acute upper GI bleeding due to tumours: short‐term success and long‐term recurrence with or without endoscopic therapy
Sheibani S, Kim JJ, Chen B, Park S, Saberi B, Keyashian K, Buxbaum J, Laine L. Natural history of acute upper GI bleeding due to tumours: short‐term success and long‐term recurrence with or without endoscopic therapy. Alimentary Pharmacology & Therapeutics 2013, 38: 144-150. PMID: 23710797, DOI: 10.1111/apt.12347.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingEndoscopic therapyHaemodynamic instabilityMalignant tumorsBiopsy-proven malignant tumorsAcute upper GISubstantial blood lossLong-term recurrenceYears of ageInitial haemostasisRepeat hospitalisationActive bleedingGastrointestinal bleedingIndex hospitalisationEndoscopic findingsMetastatic diseaseUpper endoscopyBlood lossConsecutive patientsEndoscopic treatmentUpper GIEndoscopy databaseRisk factorsPatientsMultivariate analysis
2010
Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID‐associated upper GI clinical events in a long‐term prospective study of 34 701 arthritis patients. Alimentary Pharmacology & Therapeutics 2010, 32: 1240-1248. PMID: 20955443, DOI: 10.1111/j.1365-2036.2010.04465.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArthritisCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibFemaleGastrointestinal DiseasesHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesPyridinesRisk FactorsSulfonesTime FactorsUpper Gastrointestinal TractConceptsClinical eventsRisk factorsLow-dose aspirin useDouble-blind randomized trialsLong-term prospective studiesCox proportional hazards modelNonsteroidal anti-inflammatory drugsDiscontinuation of NSAIDsPredictors of discontinuationUpper GI eventsLow-dose aspirinPotential risk factorsProportional hazards modelAnti-inflammatory drugsAspirin useGI eventsPatient characteristicsArthritis patientsTreat analysisRandomized trialsRheumatoid arthritisProspective studyGI effectsDyspepsiaHazards model
2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
LAINE L, CONNORS L, GRIFFIN MR, CURTIS SP, KAUR A, CANNON CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Alimentary Pharmacology & Therapeutics 2009, 30: 767-774. PMID: 19594486, DOI: 10.1111/j.1365-2036.2009.04090.x.Peer-Reviewed Original ResearchBaseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program
Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. European Journal Of Heart Failure 2009, 11: 542-550. PMID: 19380329, DOI: 10.1093/eurjhf/hfp054.Peer-Reviewed Original ResearchConceptsCongestive heart failureHistory of CHFHazard ratioHeart failureRisk markersRisk factorsIncidence of CHFRisk of CHFMultivariate analysisCox proportional hazards modelNon-steroidal anti-inflammatory drugsBaseline risk factorsHistory of hypertensionEmergency room visitsSignificant risk factorsDose-related increaseSignificant risk markerProportional hazards modelAnti-inflammatory drugsImpact of treatmentEtoricoxib 60CHF hospitalizationBaseline factorsRoom visitsCHF eventsFactors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study
Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. Journal Of Hypertension 2009, 27: 886-893. PMID: 19516186, DOI: 10.1097/hjh.0b013e328325d831.Peer-Reviewed Original ResearchConceptsCalcium channel blockersHistory of hypertensionBlood pressureAntihypertensive classesDiastolic BPRisk factorsAntihypertensive drug classesHypertension risk factorsDiastolic blood pressureSystolic blood pressureBlood pressure changesAntihypertensive medicationsMultinational EtoricoxibNSAID therapyHypertensive effectAntihypertensive effectArthritis patientsDrug classesChannel blockersNonsignificant decreaseMultivariate analysisSBPLong-term studiesEtoricoxibHypertension
2008
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. The American Journal Of Gastroenterology 2008, 103: ajg2008576. PMID: 18853980, DOI: 10.1111/j.1572-0241.2008.02200.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonselective nonsteroidal antiinflammatory drugsNonsteroidal antiinflammatory drugsGI risk factorsNonsteroidal anti-inflammatory drugsCV riskHigh CV riskProton pump inhibitorsAnti-inflammatory drugsRisk factorsCyclooxygenase-2- selective nonsteroidal antiinflammatory drugsSelective nonsteroidal antiinflammatory drugsCardiovascular safety issuesMultidisciplinary international panelPatient's CV riskClinical practice recommendationsManagement of patientsAnti-platelet agentsGI complicationsCardiovascular effectsGI riskInternational working partyPump inhibitorsTreatment strategiesAntiinflammatory drugsPatientsLower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac
Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac. Gastroenterology 2008, 135: 1517-1525. PMID: 18823986, DOI: 10.1053/j.gastro.2008.07.067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalConfidence IntervalsCyclooxygenase InhibitorsDiclofenacDose-Response Relationship, DrugEtoricoxibFemaleFollow-Up StudiesGastrointestinal HemorrhageHumansIncidenceMaleMiddle AgedOdds RatioOsteoarthritisProspective StudiesPyridinesRisk FactorsSulfonesTreatment OutcomeConceptsLower GI eventsClinical eventsGI eventsRisk factorsCOX-2 selective inhibitorsBlinded adjudication committeeLower Gastrointestinal EventsTraditional NSAID diclofenacUpper GI eventsDouble-blind trialSignificant risk factorsMajor risk factorAnti-inflammatory drugsSelective inhibitorNonsteroidal anti-inflammatory drug diclofenacGastrointestinal eventsNSAID useProspective trialMultivariable analysisRheumatoid arthritisAdjudication committeeMean durationCyclo-oxygenaseNSAID diclofenacAbstractText
2007
Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed
Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of Proton Pump Inhibitor Use in Patients With Acute Coronary Syndromes Based on Risk Factors for Gastrointestinal Bleed. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2007, 6: 169-172. PMID: 18091407, DOI: 10.1097/hpc.0b013e318159921e.Peer-Reviewed Original ResearchConceptsUse of PPIsAcute coronary syndromeProton pump inhibitorsGI risk factorsRisk factorsCoronary syndromeHigh GI risk patientsProton pump inhibitor useNonsteroidal anti-inflammatory agentsInfection Therapy-ThrombolysisLong-term bleedingPrior GI eventsDual antiplatelet therapyUse of anticoagulantsAnti-inflammatory agentsAtorvastatin EvaluationAntiplatelet therapyGastrointestinal bleedGastrointestinal bleedingGI bleedingGI eventsInhibitor useRisk patientsTrials databasesPump inhibitors
2006
GI Risk and Risk Factors of NSAIDs
Laine L. GI Risk and Risk Factors of NSAIDs. Journal Of Cardiovascular Pharmacology 2006, 47: s60-s66. PMID: 16785831, DOI: 10.1097/00005344-200605001-00011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI eventsClinical eventsNSAID useGI eventsRisk factorsMultiple nonsteroidal anti-inflammatory drugsNon-NSAID analgesicsUpper GI symptomsUse of coxibsUpper gastrointestinal complicationsUse of corticosteroidsRegular NSAID useImportant risk factorLowest effective doseAnti-inflammatory drugsGastrointestinal complicationsGI symptomsAnnual incidenceRisk stratificationGI riskRelative riskPrior historyEffective doseOlder age
2004
The epidemiology of ischaemic colitis
Higgins PD, Davis KJ, Laine L. The epidemiology of ischaemic colitis. Alimentary Pharmacology & Therapeutics 2004, 19: 729-738. PMID: 15043513, DOI: 10.1111/j.1365-2036.2004.01903.x.Peer-Reviewed Original ResearchConceptsIschemic colitisRisk factorsPopulation-based sampleGeneral populationPopulation incidenceChronic obstructive pulmonary diseaseCo-morbid conditionsIrritable bowel syndromeObstructive pulmonary diseasePopulation-based studyGeneral population incidenceBowel syndromePulmonary diseaseCase seriesBaseline incidenceCase reportAdvanced ageVascular surgeryColitisEligible articlesIncidencePopulation samplePrevalenceRiskBibliographic databases
2002
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002, 123: 1006-1012. PMID: 12360461, DOI: 10.1053/gast.2002.36013.Peer-Reviewed Original ResearchConceptsUpper GI eventsClinical upper GI eventsSelective cyclooxygenase-2 inhibitorHigh-risk patientsGI eventsRisk factorsCyclooxygenase-2 inhibitorClinical characteristicsRheumatoid arthritisClinical eventsNonsteroidal anti-inflammatory drugsClinical GI eventsRisk of NSAIDUpper GI complicationsLow-risk patientsSevere rheumatoid arthritisPatients' clinical characteristicsRheumatoid arthritis patientsAbsolute risk reductionLow-risk subgroupsAnti-inflammatory drugsIndividual risk factorsRisk of eventsGI complicationsNonselective NSAIDsRandomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: Is local tamponade enough?
Laine L, Estrada R. Randomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: Is local tamponade enough? Gastrointestinal Endoscopy 2002, 55: 6-10. PMID: 11756906, DOI: 10.1067/mge.2002.120390.Peer-Reviewed Original ResearchConceptsSaline solution injectionSaline solution groupNormal saline solutionBipolar electrocoagulationLocal tamponadeNonbleeding visible vesselIndependent risk factorSolution injectionSolution groupTreatment of patientsSaline solutionMajor bleedingActive bleedingEndoscopic injectionHospital daysStandard therapyUlcer sizeLack of injuryClinical evidenceVisible vesselRisk factorsEffective treatmentPatientsBleedingUlcers
2000
Influence of H. pylori and other potential risk factors on clinical gi events in a double-blind outcome study of rofecoxib VS. Naproxen
Laine L, Bombardier C, Hawkey C, Shapiro D, Reicin A. Influence of H. pylori and other potential risk factors on clinical gi events in a double-blind outcome study of rofecoxib VS. Naproxen. Gastroenterology 2000, 118: a862. DOI: 10.1016/s0016-5085(00)85588-2.Peer-Reviewed Original Research